{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,24]],"date-time":"2026-05-24T10:05:07Z","timestamp":1779617107649,"version":"3.53.1"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme United Kingdom","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Virology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.virol.2025.110710","type":"journal-article","created":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T13:18:27Z","timestamp":1760015907000},"page":"110710","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Impact of baseline humoral immunity on treatment outcomes with molnupiravir in the MOVe-OUT randomized, controlled trial"],"prefix":"10.1016","volume":"613","author":[{"given":"Matthew G.","family":"Johnson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie M.","family":"Strizki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W.","family":"Hilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Carmelitano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle L.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik J.","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Paschke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carisa S.","family":"De Anda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.virol.2025.110710_bib1","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/j.cmi.2024.06.018","article-title":"Effectiveness and safety of molnupiravir in the intended-use population: an observational cohort study","volume":"30","author":"Abu Ahmad","year":"2024","journal-title":"Clin. Microbiol. Infect."},{"issue":"6","key":"10.1016\/j.virol.2025.110710_bib2","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1093\/cid\/ciad780","article-title":"Viral and host factors are associated with mortality in hospitalized patients with COVID-19","volume":"78","author":"Aggarwal","year":"2024","journal-title":"Clin. Infect. Dis."},{"issue":"24","key":"10.1016\/j.virol.2025.110710_bib3","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01348-19","article-title":"Small-molecule antiviral beta-d-N (4)-hydroxycytidine inhibits a proofreading-intact coronavirus with a high genetic barrier to resistance","volume":"93","author":"Agostini","year":"2019","journal-title":"J. Virol."},{"issue":"6","key":"10.1016\/j.virol.2025.110710_bib4","article-title":"Longitudinal analysis of humoral immunity against SARS-CoV-2 spike in convalescent individuals up to 8 months post-symptom onset","volume":"2","author":"Anand","year":"2021","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.virol.2025.110710_bib5","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-77739-y","article-title":"Recurrent SARS-CoV-2 RNA positivity after COVID-19: a systematic review and meta-analysis","volume":"10","author":"Azam","year":"2020","journal-title":"Sci. Rep."},{"issue":"9","key":"10.1016\/j.virol.2025.110710_bib6","doi-asserted-by":"crossref","DOI":"10.3390\/v14091966","article-title":"SARS-CoV-2 spike and nucleocapsid antibody response in vaccinated Croatian healthcare workers and infected hospitalized patients: a single center cohort study","volume":"14","author":"Brlic","year":"2022","journal-title":"Viruses"},{"issue":"3","key":"10.1016\/j.virol.2025.110710_bib7","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1177\/17407745251313925","article-title":"Impact of differences between interim and post-interim analysis populations on outcomes of a group sequential trial: example of the MOVe-OUT study","volume":"22","author":"Caraco","year":"2025","journal-title":"Clin. Trials"},{"key":"10.1016\/j.virol.2025.110710_bib8","series-title":"StatPearls","article-title":"Features, evaluation, and treatment of coronavirus (COVID-19)","author":"Cascella","year":"2022"},{"issue":"2","key":"10.1016\/j.virol.2025.110710_bib9","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1093\/infdis\/jiae192","article-title":"Characterization of treatment resistance and viral kinetics in the setting of single-active versus dual-active monoclonal antibodies against severe acute respiratory syndrome coronavirus 2","volume":"230","author":"Choudhary","year":"2024","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.virol.2025.110710_bib10","doi-asserted-by":"crossref","DOI":"10.1126\/science.abf4063","article-title":"Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection","author":"Dan","year":"2021","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.virol.2025.110710_bib11","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofad625","article-title":"Association of nirmaltrevir\/ritonavir treatment and COVID-19-neutralizing antibody titers in a longitudinal health care worker cohort","volume":"11","author":"Decker","year":"2024","journal-title":"Open Forum Infect. Dis."},{"key":"10.1016\/j.virol.2025.110710_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2021.108814","article-title":"Longitudinal observation of antibody responses for 14 months after SARS-CoV-2 infection","volume":"230","author":"Dehgani-Mobaraki","year":"2021","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.virol.2025.110710_bib13","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.virol.2022.12.003","article-title":"Long-term persistence of IgG antibodies in recovered COVID-19 individuals at 18 months post-infection and the impact of two-dose BNT162b2 (Pfizer-BioNTech) mRNA vaccination on the antibody response: analysis using fixed-effects linear regression model","volume":"578","author":"Dehgani-Mobaraki","year":"2023","journal-title":"Virology"},{"issue":"2","key":"10.1016\/j.virol.2025.110710_bib14","doi-asserted-by":"crossref","DOI":"10.3390\/v15020504","article-title":"Understanding the SARS-CoV-2 virus neutralizing antibody response: lessons to be learned from HIV and respiratory syncytial virus","volume":"15","author":"Dimmock","year":"2023","journal-title":"Viruses"},{"issue":"11","key":"10.1016\/j.virol.2025.110710_bib15","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1038\/s41564-021-00974-0","article-title":"Neutralizing antibody activity in convalescent sera from infection in humans with SARS-CoV-2 and variants of concern","volume":"6","author":"Dupont","year":"2021","journal-title":"Nat. Microbiol."},{"issue":"2","key":"10.1016\/j.virol.2025.110710_bib16","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S1473-3099(20)30943-9","article-title":"Persistence of IgG response to SARS-CoV-2","volume":"21","author":"Duysburgh","year":"2021","journal-title":"Lancet Infect. Dis."},{"issue":"19","key":"10.1016\/j.virol.2025.110710_bib17","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1056\/NEJMoa2113017","article-title":"Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase","volume":"385","author":"El Sahly","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.virol.2025.110710_bib18","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1093\/cid\/ciac663","article-title":"Clinical, virologic, and immunologic evaluation of symptomatic coronavirus disease 2019 rebound following nirmatrelvir\/ritonavir treatment","volume":"76","author":"Epling","year":"2023","journal-title":"Clin. Infect. Dis."},{"issue":"1","key":"10.1016\/j.virol.2025.110710_bib19","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.28233","article-title":"Antiviral treatment of COVID-19 is associated with lack of immune response","volume":"95","author":"Erdik","year":"2023","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.virol.2025.110710_bib20","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.614436","article-title":"Longitudinal profiling of antibody response in patients with COVID-19 in a tertiary care hospital in Beijing, China","volume":"12","author":"Feng","year":"2021","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.virol.2025.110710_bib21","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202317580","article-title":"Nirmatrelvir treatment of SARS-CoV-2-infected mice blunts antiviral adaptive immune responses","volume":"15","author":"Fumagalli","year":"2023","journal-title":"EMBO Mol. Med."},{"issue":"2","key":"10.1016\/j.virol.2025.110710_bib22","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/s41423-023-01098-7","article-title":"The interplay of drug therapeutics and immune responses to SARS-CoV-2","volume":"21","author":"Fumagalli","year":"2024","journal-title":"Cell. Mol. Immunol."},{"issue":"54","key":"10.1016\/j.virol.2025.110710_bib23","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abf8891","article-title":"Rapid generation of durable B cell memory to SARS-CoV-2 spike and nucleocapsid proteins in COVID-19 and convalescence","volume":"5","author":"Hartley","year":"2020","journal-title":"Sci. Immunol."},{"issue":"7","key":"10.1016\/j.virol.2025.110710_bib24","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.3201\/eid2907.230173","article-title":"Trajectory and demographic correlates of antibodies to SARS-CoV-2 nucleocapsid in recently infected blood donors, United States","volume":"29","author":"Haynes","year":"2023","journal-title":"Emerg. Infect. Dis."},{"issue":"12","key":"10.1016\/j.virol.2025.110710_bib25","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202201973RR","article-title":"The SARS-CoV-2 nucleocapsid protein suppresses innate immunity by remodeling stress granules to atypical foci","volume":"37","author":"He","year":"2023","journal-title":"FASEB J."},{"issue":"52","key":"10.1016\/j.virol.2025.110710_bib26","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abe0367","article-title":"Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients","volume":"5","author":"Iyer","year":"2020","journal-title":"Sci. Immunol."},{"issue":"6","key":"10.1016\/j.virol.2025.110710_bib27","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1056\/NEJMoa2116044","article-title":"Molnupiravir for oral treatment of COVID-19 in nonhospitalized patients","volume":"386","author":"Jayk Bernal","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.virol.2025.110710_bib28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0305077","article-title":"A comparison study of temporal trends of SARS-CoV2 RNAemia and biomarkers to predict success and failure of high flow oxygen therapy among patients with moderate to severe COVID-19","volume":"19","author":"Koyama","year":"2024","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.virol.2025.110710_bib29","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1016\/S2666-7568(21)00282-8","article-title":"Prevalence and duration of detectable SARS-CoV-2 nucleocapsid antibodies in staff and residents of long-term care facilities over the first year of the pandemic (VIVALDI study): prospective cohort study in England","volume":"3","author":"Krutikov","year":"2022","journal-title":"Lancet. Health. Longev."},{"issue":"2","key":"10.1016\/j.virol.2025.110710_bib30","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41423-023-01095-w","article-title":"B-cell and antibody responses to SARS-CoV-2: infection, vaccination, and hybrid immunity","volume":"21","author":"Lapuente","year":"2024","journal-title":"Cell. Mol. Immunol."},{"issue":"1","key":"10.1016\/j.virol.2025.110710_bib31","doi-asserted-by":"crossref","first-page":"6044","DOI":"10.1038\/s41467-020-19943-y","article-title":"Dynamic changes in anti-SARS-CoV-2 antibodies during SARS-CoV-2 infection and recovery from COVID-19","volume":"11","author":"Li","year":"2020","journal-title":"Nat. Commun."},{"issue":"9","key":"10.1016\/j.virol.2025.110710_bib32","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.35077","article-title":"Nirmatrelvir or molnupiravir use and severe outcomes from omicron infections","volume":"6","author":"Lin","year":"2023","journal-title":"JAMA Netw. Open"},{"issue":"4","key":"10.1016\/j.virol.2025.110710_bib33","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1002\/jmv.26646","article-title":"Characterization of antibody responses to SARS-CoV-2 in convalescent COVID-19 patients","volume":"93","author":"Liu","year":"2021","journal-title":"J. Med. Virol."},{"issue":"5","key":"10.1016\/j.virol.2025.110710_bib34","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.14393","article-title":"Analysis of all-cause hospitalization and death among nonhospitalized patients with type 2 diabetes and SARS-CoV-2 infection treated with molnupiravir or nirmatrelvir-ritonavir during the omicron wave in Hong Kong","volume":"6","author":"Lui","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.virol.2025.110710_bib35","doi-asserted-by":"crossref","DOI":"10.1002\/rmv.2431","article-title":"SARS-CoV-2 nucleocapsid: biological functions and implication for disease diagnosis and vaccine design","author":"Maghsood","year":"2023","journal-title":"Rev. Med. Virol."},{"issue":"6","key":"10.1016\/j.virol.2025.110710_bib36","doi-asserted-by":"crossref","DOI":"10.3390\/microorganisms12061146","article-title":"Clinico-virological outcomes and mutational profile of SARS-CoV-2 in adults treated with ribavirin aerosol for COVID-19 pneumonia","volume":"12","author":"Morsica","year":"2024","journal-title":"Microorganisms"},{"issue":"10","key":"10.1016\/j.virol.2025.110710_bib37","doi-asserted-by":"crossref","DOI":"10.3390\/microorganisms11102607","article-title":"Does nirmatrelvir\/ritonavir influence the immune response against SARS-CoV-2, independently from rebound?","volume":"11","author":"Panza","year":"2023","journal-title":"Microorganisms"},{"issue":"12","key":"10.1016\/j.virol.2025.110710_bib38","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1093\/infdis\/jiad324","article-title":"Real-world effectiveness of molnupiravir and nirmatrelvir\/ritonavir as treatments for COVID-19 in patients at high risk","volume":"228","author":"Paraskevis","year":"2023","journal-title":"J. Infect. Dis."},{"issue":"11","key":"10.1016\/j.virol.2025.110710_bib39","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.01138-21","article-title":"The fall in antibody rsponse to SARS-CoV-2: a longitudinal study of ssymptomatic to critically ill patients up to 10 months after recovery","volume":"59","author":"Peghin","year":"2021","journal-title":"J. Clin. Microbiol."},{"issue":"12","key":"10.1016\/j.virol.2025.110710_bib40","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2023-076892","article-title":"Protection of the third-dose and fourth-dose mRNA vaccines against SARS-CoV-2 omicron subvariant: a systematic review and meta-analysis","volume":"13","author":"Rahman","year":"2023","journal-title":"BMJ Open"},{"issue":"1","key":"10.1016\/j.virol.2025.110710_bib41","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1186\/s12879-023-08538-9","article-title":"Comparison between available early antiviral treatments in outpatients with SARS-CoV-2 infection: a real-life study","volume":"23","author":"Rinaldi","year":"2023","journal-title":"BMC Infect. Dis."},{"issue":"6","key":"10.1016\/j.virol.2025.110710_bib42","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.cell.2022.01.018","article-title":"Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination","volume":"185","author":"Roltgen","year":"2022","journal-title":"Cell"},{"issue":"13","key":"10.1016\/j.virol.2025.110710_bib43","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.160108","article-title":"Molnupiravir inhibits SARS-CoV-2 variants including omicron in the hamster model","volume":"7","author":"Rosenke","year":"2022","journal-title":"JCI Insight"},{"issue":"5","key":"10.1016\/j.virol.2025.110710_bib44","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.02890-20","article-title":"Assessment of S1-, S2-, and NCP-specific IgM, IgA, and IgG antibody kinetics in acute SARS-CoV-2 infection by a microarray and twelve other immunoassays","volume":"59","author":"Semmler","year":"2021","journal-title":"J. Clin. Microbiol."},{"issue":"541","key":"10.1016\/j.virol.2025.110710_bib45","doi-asserted-by":"crossref","first-page":"eabb5883","DOI":"10.1126\/scitranslmed.abb5883","article-title":"An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice","volume":"12","author":"Sheahan","year":"2020","journal-title":"Sci. Transl. Med."},{"issue":"5","key":"10.1016\/j.virol.2025.110710_bib46","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/s41385-022-00511-0","article-title":"Systemic and mucosal IgA responses are variably induced in response to SARS-CoV-2 mRNA vaccination and are associated with protection against subsequent infection","volume":"15","author":"Sheikh-Mohamed","year":"2022","journal-title":"Mucosal Immunol."},{"key":"10.1016\/j.virol.2025.110710_bib47","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1093\/infdis\/jiae198","article-title":"SARS-CoV-2 RNA and nucleocapsid antigen are blood biomarkers associated with severe disease outcomes that improve in response to remdesivir","volume":"230","author":"Singh","year":"2024","journal-title":"J. Infect. Dis."},{"issue":"35","key":"10.1016\/j.virol.2025.110710_bib48","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2024.29.35.2300690","article-title":"Post-vaccination, post-infection and hybrid immunity against severe cases of COVID-19 and long COVID after infection with SARS-CoV-2 omicron subvariants, Czechia, December 2021 to August 2023","volume":"29","author":"Smid","year":"2024","journal-title":"Euro Surveill."},{"issue":"1","key":"10.1016\/j.virol.2025.110710_bib49","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1038\/s41467-024-45641-0","article-title":"Randomized controlled trial of molnupiravir SARS-CoV-2 viral and antibody response in at-risk adult outpatients","volume":"15","author":"Standing","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.virol.2025.110710_bib50","series-title":"Idweek","article-title":"Molnupiravir exhibits a high barrier to the development of SARS-CoV-2 resistance in vitro","author":"Strizki","year":"2022"},{"issue":"12","key":"10.1016\/j.virol.2025.110710_bib51","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1007\/s40121-023-00891-1","article-title":"Virologic outcomes with molnupiravir in non-hospitalized adult patients with COVID-19 from the randomized, placebo-controlled MOVe-OUT trial","volume":"12","author":"Strizki","year":"2023","journal-title":"Infect. Dis. Ther."},{"issue":"19","key":"10.1016\/j.virol.2025.110710_bib52","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1056\/NEJMoa2110345","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months","volume":"385","author":"Thomas","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.virol.2025.110710_bib53","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1186\/s12889-023-15626-7","article-title":"Global prevalence of coronavirus disease 2019 reinfection: a systematic review and meta-analysis","volume":"23","author":"Ukwishaka","year":"2023","journal-title":"BMC Public Health"},{"issue":"3","key":"10.1016\/j.virol.2025.110710_bib54","doi-asserted-by":"crossref","first-page":"309","DOI":"10.3390\/epidemiologia4030031","article-title":"Real-world utilization of molnupiravir during the COVID-19 omicron surge in Israel","volume":"4","author":"Weil","year":"2023","journal-title":"Epidemiologia (Basel)"},{"issue":"10359","key":"10.1016\/j.virol.2025.110710_bib55","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/S0140-6736(22)01586-0","volume":"400","author":"Wong","year":"2022","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.virol.2025.110710_bib57","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1038\/s41467-021-22034-1","article-title":"SARS-CoV-2 infection induces sustained humoral immune responses in convalescent patients following symptomatic COVID-19","volume":"12","author":"Wu","year":"2021","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.virol.2025.110710_bib58","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12985-023-01968-6","article-title":"The SARS-CoV-2 nucleocapsid protein: its role in the viral life cycle, structure and functions, and use as a potential target in the development of vaccines and diagnostics","volume":"20","author":"Wu","year":"2023","journal-title":"Virol. J."},{"issue":"8","key":"10.1016\/j.virol.2025.110710_bib59","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1038\/s41591-020-0949-6","article-title":"Seroprevalence of immunoglobulin M and G antibodies against SARS-CoV-2 in China","volume":"26","author":"Xu","year":"2020","journal-title":"Nat. Med."},{"issue":"3","key":"10.1016\/j.virol.2025.110710_bib60","first-page":"233","article-title":"Investigation of durability of SARS-CoV-2-specific IgG and IgM antibodies in recovered COVID-19 patients: a prospective study","volume":"14","author":"Zamani","year":"2022","journal-title":"Avicenna J. Med. Biotechnol. (AJMB)"},{"issue":"14","key":"10.1016\/j.virol.2025.110710_bib61","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1016\/j.cell.2022.05.022","article-title":"Humoral and cellular immune memory to four COVID-19 vaccines","volume":"185","author":"Zhang","year":"2022","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.virol.2025.110710_bib62","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41392-022-00878-3","article-title":"SARS-CoV-2 NSP5 and N protein counteract the RIG-I signaling pathway by suppressing the formation of stress granules","volume":"7","author":"Zheng","year":"2022","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.virol.2025.110710_bib63","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2024.1457266","article-title":"Meta-analysis of hybrid immunity to mitigate the risk of omicron variant reinfection","volume":"12","author":"Zheng","year":"2024","journal-title":"Front. Public Health"},{"issue":"2","key":"10.1016\/j.virol.2025.110710_bib64","doi-asserted-by":"crossref","DOI":"10.1128\/Spectrum.00590-21","article-title":"Kinetics of SARS-CoV-2 specific and neutralizing antibodies over seven months after symptom onset in COVID-19 patients","volume":"9","author":"Zhu","year":"2021","journal-title":"Microbiol. Spectr."}],"updated-by":[{"DOI":"10.1016\/j.virol.2025.110737","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000}},{"DOI":"10.1016\/j.virol.2025.110737","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000}}],"container-title":["Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0042682225003241?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0042682225003241?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,24]],"date-time":"2026-05-24T09:49:53Z","timestamp":1779616193000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0042682225003241"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":63,"alternative-id":["S0042682225003241"],"URL":"https:\/\/doi.org\/10.1016\/j.virol.2025.110710","relation":{},"ISSN":["0042-6822"],"issn-type":[{"value":"0042-6822","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of baseline humoral immunity on treatment outcomes with molnupiravir in the MOVe-OUT randomized, controlled trial","name":"articletitle","label":"Article Title"},{"value":"Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.virol.2025.110710","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"110710"}}